Document is current
Any future updates will be listed below
-
Authors
Powell, Rachel E
Tai, Yi Yin
Kennedy, Jason N
Seymour, Christopher W
Chan, Stephen Y https://orcid.org/0000-0002-9520-7527
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (GM119519, GM104022)
NHLBI Division of Intramural Research (HL124021, HL122596)
American Heart Association (18EIA33900027)
- License Information
-
More Information
Article History
Received: 11 September 2022
Accepted: 13 September 2022
First Online: 4 October 2022
Declarations
:
: This study was approved by the University of Pittsburgh Human Research Protection Office. The data were obtained under a waiver of informed consent because the data were deidentified and with authorization under the Health Insurance Portability and Accountability Act.
: Not applicable.
: S.Y.C. has served as a consultant for Acceleron Pharma and United Therapeutics. S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics. S.Y.C. has held research grants from Actelion, Bayer, and Pfizer. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. The other authors declare no competing interests.
